See more : Guangzhou Sie Consulting Co., Ltd. (300687.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of MannKind Corporation (MNKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MannKind Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rusoro Mining Ltd. (RMLFF) Income Statement Analysis – Financial Results
- Sintx Technologies, Inc. (SINT) Income Statement Analysis – Financial Results
- Sportsman’s Warehouse Holdings, Inc. (SPWH) Income Statement Analysis – Financial Results
- Mitsui Chemicals, Inc. (4183.T) Income Statement Analysis – Financial Results
- Canadian Utilities Limited (CU-X.TO) Income Statement Analysis – Financial Results
MannKind Corporation (MNKD)
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.75M | 174.76M | 0.00 | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Cost of Revenue | 62.77M | 57.50M | 38.86M | 24.64M | 27.98M | 20.48M | 17.23M | 50.09M | 140.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 136.19M | 42.27M | 36.59M | 40.50M | 35.06M | 7.38M | -5.48M | 124.67M | -140.41M | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Gross Profit Ratio | 68.45% | 42.37% | 48.49% | 62.17% | 55.62% | 26.49% | -46.68% | 71.34% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 31.28M | 19.72M | 12.31M | 6.25M | 6.90M | 8.74M | 14.12M | 14.92M | 29.67M | 100.24M | 109.72M | 101.52M | 99.96M | 112.28M | 156.33M | 250.44M | 256.84M | 191.80M | 95.35M | 59.27M | 45.61M | 42.72M | 19.76M | 20.54M |
| General & Administrative | 42.54M | 37.72M | 31.89M | 22.88M | 0.00 | 79.72M | 74.96M | 27.07M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 51.78M | 53.75M | 45.53M | 34.37M | 0.00 | 0.00 | 0.00 | 19.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 94.31M | 91.47M | 77.42M | 59.04M | 74.67M | 79.72M | 74.96M | 46.93M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 20.70M | 13.22M | 0.00 | 4.85M |
| Other Expenses | 1.92M | -102.00K | 339.00K | 23.00K | -926.00K | -437.00K | 13.00K | -597.00K | 1.37M | 1.68M | -635.00K | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.60M | 111.19M | 90.07M | 65.29M | 81.57M | 88.44M | 88.86M | 59.58M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Cost & Expenses | 190.28M | 168.69M | 128.93M | 89.93M | 109.55M | 108.92M | 106.09M | 109.67M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Interest Income | 6.15M | 2.51M | 112.00K | 167.00K | 997.00K | 501.00K | 293.00K | 85.00K | 18.00K | 9.00K | 8.00K | 7.00K | 18.00K | 40.00K | 70.00K | 5.13M | 17.78M | 0.00 | 3.71M | 932.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.16M | 24.77M | 16.58M | 9.47M | 10.91M | 9.44M | 13.28M | 18.48M | 24.13M | 20.44M | 21.46M | 21.63M | 21.82M | 17.38M | 10.45M | 2.34M | 3.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.54M | 6.29M | 3.26M | 2.98M | 2.78M | 1.70M | 1.80M | 2.40M | 13.28M | 18.58M | 14.06M | 14.40M | 15.91M | 17.32M | 18.73M | 12.29M | 8.97M | 8.52M | 7.39M | 7.18M | 7.66M | 5.07M | 50.08M | -204.00K |
| EBITDA | 15.13M | -56.34M | -61.09M | -45.01M | -38.22M | -75.60M | -102.21M | 146.54M | -344.66M | -160.18M | -155.97M | -133.74M | -123.68M | -135.86M | -190.93M | -288.41M | -280.81M | -225.18M | -106.95M | -68.81M | -58.63M | -51.35M | 289.00K | -25.45M |
| EBITDA Ratio | 7.60% | -66.66% | -71.06% | -37.75% | -73.67% | -280.49% | -800.67% | 36.95% | 0.00% | 0.00% | 0.00% | -423,268.57% | -281,042.00% | -163,196.77% | 0.00% | -1,503,180.00% | -2,981,870.00% | -225,388.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.65% | -16,523.38% |
| Operating Income | 8.68M | -68.92M | -53.48M | -24.79M | -46.51M | -76.60M | -108.19M | 67.26M | -344.66M | -179.63M | -169.40M | -146.96M | -140.54M | -152.50M | -209.78M | -305.77M | -307.36M | -233.70M | -118.12M | -77.15M | -66.31M | -207.37M | -49.79M | -25.24M |
| Operating Income Ratio | 4.36% | -69.08% | -70.89% | -38.05% | -73.78% | -274.94% | -921.15% | 38.49% | 0.00% | 0.00% | 0.00% | -419,885.71% | -281,078.00% | -163,976.34% | 0.00% | -1,528,825.00% | -3,073,570.00% | -233,697.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,273.62% | -16,390.91% |
| Total Other Income/Expenses | -19.06M | -23.29M | -33.90M | -9.55M | -7.31M | -10.14M | -9.09M | 58.40M | -23.79M | -18.76M | -22.09M | -22.81M | -20.27M | -18.06M | -10.33M | 2.73M | 14.17M | 3.15M | 3.79M | 1.16M | 434.00K | 1.10M | 1.55M | 583.00K |
| Income Before Tax | -10.38M | -87.40M | -80.93M | -57.46M | -51.90M | -86.74M | -117.28M | 125.66M | -368.45M | -198.38M | -191.49M | -169.77M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.54M | -114.34M | -75.99M | -65.88M | -206.26M | -48.24M | -24.66M |
| Income Before Tax Ratio | -5.22% | -87.60% | -107.27% | -88.20% | -82.34% | -311.34% | -998.57% | 71.91% | 0.00% | 0.00% | 0.00% | -485,068.57% | -321,608.00% | -183,397.85% | 0.00% | -1,515,185.00% | -2,931,870.00% | -230,543.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,798.47% | -16,012.34% |
| Income Tax Expense | 1.56M | 24.77M | 10.87M | -218.00K | 7.83M | 240.00K | 51.00K | 13.72M | 12.22M | 3.55M | 6.77M | -408.00K | 5.91M | 738.00K | -8.28M | 2.00K | 3.00K | 5.00K | 1.00K | 1.00K | 1.00K | 2.00K | 2.00K | 2.00K |
| Net Income | -11.94M | -112.17M | -91.79M | -57.24M | -59.73M | -86.98M | -117.33M | 125.66M | -368.45M | -198.38M | -191.49M | -169.37M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.55M | -114.34M | -75.99M | -65.88M | -206.27M | -48.25M | -24.66M |
| Net Income Ratio | -6.00% | -112.43% | -121.67% | -87.87% | -94.75% | -312.20% | -999.00% | 71.91% | 0.00% | 0.00% | 0.00% | -483,902.86% | -321,608.00% | -183,397.85% | 0.00% | -1,515,195.00% | -2,931,900.00% | -230,548.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,799.08% | -16,013.64% |
| EPS | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| EPS Diluted | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| Weighted Avg Shares Out | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 103.83M | 92.05M | 81.16M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
| Weighted Avg Shares Out (Dil) | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 104.25M | 92.09M | 81.23M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
Why Shares of MannKind Are Up Wednesday
MannKind had a big jump in revenue year over year. The company has benefitted from its collaboration agreement with United Therapeutics.
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today...
MannKind Corporation (MNKD) Q1 2023 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Michael Castagna - CEO Steven Binder - CFO Conference Call Participants Oren Livnat - HC Wainwright Brandon Folkes - Cantor Fitzgerald Thomas Smith...
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.
Mannkind Corporation Reports 2023 First Quarter Financial Results
1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs.
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates...
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the...
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today...
MannKind Corporation (MNKD) Q4 2022 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q4 2022 Results Conference Call February 23, 2023 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Gregory Renza - RBC...
Source: https://incomestatements.info
Category: Stock Reports